Tafluposide
| Code | Size | Price |
|---|
| TAR-T28912-5mg | 5mg | £711.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Tafluposide is a DNA topoisomerase inhibitor with anti-tumor activity.
CAS:
179067-42-6
Formula:
C45H35F10O20P
Molecular Weight:
1116.713
Purity:
0.98
SMILES:
[H][C@]12COC(=O)[C@]1([H])[C@H](c1cc(OC)c(OP(O)(O)=O)c(OC)c1)c1cc3OCOc3cc1[C@H]2O[C@@H]1O[C@@H]2COC(C)O[C@H]2[C@H](OC(=O)COc2c(F)c(F)c(F)c(F)c2F)[C@H]1OC(=O)COc1c(F)c(F)c(F)c(F)c1F
References
1. Kluza J, Mazinghien R, Irwin H, Hartley JA, Bailly C. Relationships between DNA strand breakage and apoptotic progression upon treatment of HL-60 leukemia cells with tafluposide or etoposide. Anticancer Drugs. 2006 Feb;17(2):155-64. PubMed PMID: 16428933.
2. Pujol MD, Romero M, S?nchez I. Synthesis and biological activity of new class of dioxygenated anticancer agents. Curr Med Chem Anticancer Agents. 2005 May;5(3):215-37. Review. PubMed PMID: 15992351.
3. Kruczynski A, Barret JM, Van Hille B, Chansard N, Astruc J, Menon Y, Duchier C, Cr?ancier L, Hill BT. Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II. Clin Cancer Res. 2004 May 1;10(9):3156-68. PubMed PMID: 15131057.
4. Jensen LH, Renodon-Corni?re A, Nitiss KC, Hill BT, Nitiss JL, Jensen PB, Sehested M. A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alpha. Biochem Pharmacol. 2003 Aug 15;66(4):623-31. PubMed PMID: 12906927.